Introduction
Insulin-like growth factor-1 (IGF-1) is a peptide mitogen for a number of human prostate cancer cell lines. 1 ± 3 The diverse biological effects of IGF-1 in the growth regulatory processes of the prostate are well established both at a local level and in relation to somatic cell growth, cell metabolism, the ampli®cation of local action of trophic hormones and with regard to the anti-apoptopic effects on normal and transformed prostatic epithelial cells. These biological effects are mediated through IGF-1 receptors. 4 Most of the IGF-1 in the circulation is synthesized in the liver, but a small proportion is also produced locally. The majority of IGF-1 in the circulation is bound to speci®c IGF-binding proteins (IGFBP-1 ± 7) and only a small fraction remains unbound. The bioavailability of IGF-1 to the target tissues is modulated by the af®nity of IGF-1 for these IGFBPs and the IGFBP-3 is recognized as the major binding protein for the transportation of IGF-1 in the circulation.
The IGF-1 network, the interaction between IGF-1 and the family of IGF-binding proteins and IGF-receptors, appears to play an important role in the control of cellular proliferation and has been implicated in the promotion of cancer. At the same time, the IGFBP-3 is recognized as a promoter of apoptosis. 5 It was recently shown that there is also strong association between circulating concentrations of IGF-1 and the relative risk of breast cancer in premenopausal women 6 and, moreover, of prostate cancer in men. 7 Men in the highest quartile of serum IGF-1 concentrations have approximately 4.5 times greater risk of developing cancer of the prostate than men in the lowest quartile. Although men with an elevated baseline serum prostate speci®c antigen (PSA) level are more likely to be subsequently diagnosed with prostate cancer than those with PSA levels less than 4 ng/ml, 8 the serum IGF-1 level was strongly related to risk of developing prostate cancer even among men with a serum baseline PSA concentration less than 4 ng/ml. 7 In this communication, data is presented on IGF-1 concentrations in men who were studied as part of a prostate cancer screening initiative in the County of Gwent, South Wales, who were identi®ed as having prostate cancer on the basis of a primary PSA analysis and digital rectal examination (DRE). Results are compared to those of men identi®ed with prostatic intraepithelial neoplasia (PIN) and in relation to the levels of IGF-1 in normal subjects.
Patients and methods
Blood samples were collected from men participating in a pilot screening program for the detection and management of early prostate cancer. Asymptomatic men aged between 55 and 70 y, living in the County of Gwent in South Wales, without known prostatic pathology, were identi®ed and invited to participate in the study through their general practitioners. Men attended their own general practitioner's clinic and were asked to complete an extensive life questionnaire and to give a blood sample for PSA analysis (Tandem-R assay, Hybritech, Liege, Belgium). The men then underwent a DRE conducted by an experienced urologist. If the serum PSA result was greater than 4 ng/ml, or if the DRE identi®ed an abnormality, then on the basis of these primary screening tests, the subject was referred to the Royal Gwent Hospital, Newport for transrectal ultrasound (Bruel and Kjaer 1846 with a 7 MHz multi-planar transrectal probe) scan (TRUS) of the prostate. Prostatic-TRUS-guided biopsy was performed when hypoechoic lesions were greater than 0.5 cm in size, or if there was a palpable abnormality on DRE that was isoechoic on TRUS. Only one urologist, radiologist and histopathologist were designated to perform the DREs, to review the TRUS scans and to report the biopsy results, respectively. Determinations of PSA and IGF-1 (Octeia ELISA, Immunodiagnostic Systems Ltd, Tyne & Wear, UK) were performed at the Tenovus Cancer Research Centre by an experienced analyst. The Mann ± Whitney U-rank sum test was used for the statistical analyses. Reported P-values are two-sided.
Results and discussion
Twelve general practice (GP) clinics were involved as study centres in this pilot study for the detection and management of early prostate cancer and 4060 men aged between 55 and 70 y old were identi®ed from the patient lists, by either the GP or clinic manager. These men were invited by letter from their own GP's surgery to participate in the study. Men with known prostate cancer, or with any other prostatic pathology were excluded. A total of 2063 men responded to the invitations and 2047 went on to be screened between March 1993 and April 1994. Abnormalities were identi®ed on the basis of the PSA assay and/or the DRE, in 573 men and TRUS was performed on 558 men. Of these 558 men, 225 had a prostatic TRUS-guided biopsy. From the initial screening biopsy, localized prostate cancer was detected in 57 men and PIN was identi®ed in 44 men. The clinical management provided to men with localized prostate cancer took into account their age, general health, the PSA level, Gleason score and the clinical stage of their cancer. Treatment options were surveillance, radical external beam radiotherapy, radical retropubic prostatectomy and endocrine therapy with¯utamide. Men diagnosed with PIN lesions were further monitored using PSA analysis, tests being performed every 3 months, and an annual followup prostatic biopsy was also offered.
Serum samples collected from subjects participating in the screening study were assayed for PSA, divided into aliquots (1 ml) and stored at 730 C. A set of available aliquots from patients identi®ed with PIN (n 36) and those with cancer (n 51) were used for the analysis of IGF-1. Samples for the normal subjects (n 38) were randomly selected from the serum bank. The results of the IGF-1 analysis together with the PSA determinations are presented in Figure 1 .
The mean levels of IGF-1 in normal, PIN and cancer subjects were found to be 120.6, 145.8 and 158.0 ng/ml, respectively. The corresponding PSA levels in these groups were 3.2, 5.2 and 8.3 ng/ml. The statistical analysis of the IGF-1 data revealed that there were no signi®-cant differences (signi®cance level: P`0.05 at 95% con®dence interval) either between the normal and PIN groups (P 0.1399), nor between the PIN and cancer groups (P 0.2326). There was, however, a signi®cant difference in the IGF-1 concentrations between the normal and cancer subjects (P 0.0005).
In this retrospectively designed study, the preliminary data suggest that, in prostate cancer patients, circulating IGF-1 concentrations are signi®cantly higher than those of normal controls. Although the serum IGF-1 concentrations in patients with PIN were also higher than the normal subjects, the difference was not signi®cant. Despite the extensive literature on the role of IGF-1 receptor mediated signalling in relation to carcinogenesis, the data on serum IGF-1 concentrations have not been available. Previous studies were directed primarily towards the relationship between serum IGF-1 concentrations and cancer risk, and possible risk-reduction strategies for cancer prevention, particularly in men with a high concentration of circulating IGF-1.
It is also important to improve the speci®city with regard to the diagnosis of cancer of the prostate and a combined assessment of IGF-1 and PSA concentrations may provide better differential diagnosis and offer guidance to those with suspect DRE, but normal PSA levels.
